Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome

December 2018 | Volume 17 | Issue 12 | Features | 1328 | Copyright © December 2018


Arjun Saini MS, Cynthia Ferguson PA, Kimberly Salkey MD

Eastern Virginia Medical School, Norfolk, VA

suggest that apremilast could be useful for managing chronic inflammatory diseases. The complete elimination of oral ulcers in our patient demonstrates the ability of apremilast to be useful in helping to manage refractory cases of recurrent oral ulcers in Behçet’s syndrome. As with any agents that are immunomodulatory, the possible adverse effects of apremilast should be closely monitored and further studies would be needed to evaluate the long-term effects of continuous use of apremilast for Behçet’s syndrome. The successful treatment of refractory oral ulcers with apremilast may also help to shed some light on the pathogenesis of Behçet’s syndrome with further study.

DISCLOSURE

REFERENCES

  1. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome — a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510-1518. doi:10.1056/NEJMoa1408684
  2. Taylor J, Glenny A-M, Walsh T, et al. Interventions for the management of oral ulcers in Behçet’s disease. Cochrane Database Syst Rev. 2014;(9):CD011018. doi:10.1002/14651858.CD011018.pub2
  3. Marshall SE. Behçet’s disease. Best Pract Res Clin Rheumatol. 2004;18(3):291-311. doi:10.1016/j.berh.2004.02.008
  4. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656-1662. doi:10.1136/ard.2007.080432
  5. Saenz A, Ausejo M, Shea B, Wells GA, Welch V, Tugwell P. Pharmacotherapy for Behçet’s syndrome. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 1998. doi:10.1002/14651858.CD001084
  6. Davatchi F, Abdollahi BS, Banihashemi AT, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542-549. doi:10.3109/s10165-009-0200-2
  7. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68(10):1528-1534. doi:10.1136/ard.2008.087957
  8. Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther. 2013;3(1):1-15. doi:10.1007/s13555-013-0023-0
  9. Papp K a., Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376-e383. doi:10.1111/j.1468-3083.2012.04716.

AUTHOR CORRESPONDENCE

Arjun Saini MS sainiad@evms.edu
Close Menu